STOCKHOLM--(BUSINESS WIRE)--Regulatory News: Pergamum AB, which is a portfolio company of Karolinska Development AB (STO:KDEV), announced today that it has finalized the Clinical Study Report of a randomized Phase I/II trial of LL-37 for treatment of venous leg ulcers. Patients treated with LL-37 had a statistically significant improved healing rate compared with placebo and no safety or tolerability concerns were noted, confirming the positive preliminary data reported in July this year. Chronic leg ulcers are often defined as those that fail to heal after six weeks or more of appropriate treatment. Venous leg ulcers are the most common type of hard-to-heal leg wounds, accounting for >70% of all cases in the developed world.
Help employers find you! Check out all the jobs and post your resume.
